Mushroom powder to slow cognitive decline in middle-aged and younger seniors
Official title: Study Protocol: The Efficacy of Mushroom to Reduce Cognitive Decline in At-Risk Middle-aged Adults and Young-olds Living in the Community
Run by National University of Singapore · NCT07775833 · Data updated 2026-11-12
A randomized trial will test whether daily golden oyster mushroom powder helps maintain cognitive function in adults aged 45–80 who have a family history of dementia or subjective memory concerns.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 45 Years to 80 Years |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | National University of Singapore Academic / other |
| Locations | 1 site (Singapore) |
| Status | Recruiting |
| Started | October 2026 |
| Main results expected | December 2028 |
| Study ends | December 2030 |
| Registry record updated | September 1, 2026 |
| Trial ID | NCT07775833 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are community-dwelling adults 45–80 with a family history of dementia or subjective cognitive decline, who rarely consume mushrooms and have no dementia.
✕Probably not a fit
Participants with established neurological or psychiatric disorders, gout or hyperuricemia, significant sensory/motor impairments, or mushroom allergies may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, controlled study enrolls about 600 community-dwelling adults aged 45–80 who do not have dementia and who use mushrooms infrequently. Participants are assigned to receive daily Pleurotus citrinopileatus mushroom powder for 24 months or a control condition, with outcomes focusing on cognitive function. Eligible individuals have a family history of Alzheimer's disease or self-reported worsening memory, and must not have major neurological or psychiatric conditions. The trial is conducted at a Singapore site led by the National University of Singapore. The goal is to determine if regular mushroom intake can help preserve cognitive performance over two years.
Why it matters
Potential benefit: If successful, daily mushroom supplementation could help maintain or slow cognitive decline in at-risk adults.
How similar studies have gone: Prior studies in similar areas have produced mixed results; this trial is based on exploratory evidence and aims to provide more definitive data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Community-living adult aged 45 years to 80 years, AND * (2) Family history of Alzheimer's disease or having subjective cognitive (SCD) defined as "self-reported memory problems that have been getting worse over the past year.", AND * (3) Consume mushrooms no more than once a week, AND * (4) No dementia: CDR global score equal to zero. Exclusion Criteria: * (1) Any diagnosis of neurological diseases (e.g., epilepsy, stroke) made by a clinician, OR * (2) Any diagnosis of psychiatric illnesses (e.g., depressive disorders) made by a clinician, OR * (3) Significant sensory or motor impairments, OR * (4) Known allergy to mushrooms or a history of serious food allergies, OR * (5) Participants with a history of gout, OR * (6) Diagnosed with hyperuricemia.
Where it's running
-
Tahir Foundation Building, MD1, Level 12 (12 Science Drive 2)
Singapore, Singapore Recruiting
Study contacts
- Principal investigator: Lei FEng — National University of Singapore
- Study coordinator: Jiatong Shan
- Email: e1397079@u.nus.edu
- Phone: +65 89413228
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Diabetes, Dementia, and Oxidative Stress: A look at Nox2-related markers
This study tests whether oxidative stress linked to Nox2 is related to dementia risk in adults with type 2 diabetes.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Doll Therapy for Apathy and Daily Living in Older Adults with Dementia
This study tests whether doll therapy helps reduce apathy and improves starting daily activities in older adults with dementia.
-
Aging Brain Health Initiative in Fujian
This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.